Form 4: Candel Therapeutics CEO Paul Peter Tak Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Candel Therapeutics CEO Paul Peter Tak sold 21,172 shares of common stock on January 8, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On January 8, 2025, Paul Peter Tak, CEO of Candel Therapeutics, Inc., sold 21,172 shares of common stock.
- The sale was executed at a price of $8.2182 per share.
- The transaction was conducted to cover tax withholding obligations associated with the vesting and settlement of restricted stock units, as per the issuer's mandatory sell-to-cover policy.
- Following the transaction, Tak directly owns 273,616 shares of Candel Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations, not necessarily indicative of the executive's view on the company's future prospects.
Industry Context
Sales to cover tax obligations are a common practice among executives receiving equity compensation. This transaction reflects the standard operation of equity compensation plans and tax regulations.
Stakeholder Impact
- The sale may have a minor impact on shareholders due to the increased supply of shares, but it is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 01/08/2025 | Date of the stock sale transaction. |
| 01/10/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.